期刊
EXPERIMENTAL HEMATOLOGY
卷 30, 期 7, 页码 816-823出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0301-472X(02)00818-4
关键词
-
资金
- NCI NIH HHS [P01 CA70970] Funding Source: Medline
Objective. In this study we compared the hematopoietic capacity of CD34(+) cell preparations from neonatal cord blood (CB) vs adult mobilized peripheral blood (PBSC) before and after ex vivo culture. Methods. CD34(+) cell preparations purified from CB or PBSC were cultured in serum-free medium containing FKT: FI.T-3 ligand (FL), KIT ligand (KL), and thrombopoietin (TPO). Results. After 1-4 weeks ex vivo culture, CB CD34(+) cell preparations had greatly increased numbers of total cells, CD34(+) cells, and colony-forming cells (CFC). In contrast, ex vivo-cultured PBSC CD34(+) cell preparations generated far less in vitro assessed hematopoietic capacity. Nonobese diabetic severe combined immunodeficient mouse (NOD/SCID) engrafting potential (SEP) was maintained in ex vivo-cultured CB CD34(+) cell preparations, whereas ex vivo-cultured PBSC lost SEP. CB CD34(+) cells continued to proliferate throughout 3 weeks ex vivo, whereas after 1 week, no additional cell divisions were detected in PBSC CD34(+) cells. After 3 weeks in culture, the average CB CD34(+) cell had divided more than 5 times, as compared to only 2 times for the average PBSC CD34(+) cell. Conclusion. CB CD34(+) cell preparations generated massively increased in vitro assessed hematopoietic capacity and maintained SEP during 1- to 4-week ex vivo cultures. In contrast, ex vivo-cultured PBSC CD34(+) cell preparations generated far less in vitro assessed hematopoietic capacity and decreased SEP. The differences in the in vitro proliferative indices of membrane dye-labeled CD34(+) cells from CB vs PBSC correlated with these functional differences. (C) 2002 International Society for Experimental Hematology. Published by Elsevier Science Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据